Led by Timothy Henry, MD, and Eduardo Marbán, MD, PhD, the doctors and researchers at the Smidt Heart Institute Regenerative Medicine Clinic are focused on the scientific benefits of cardiac stem cells to repair damaged or diseased tissues. The team’s clinical trials, research and investigate stem cell therapies are poised to transform the world of heart disease and save lives.
To advance this vital research, the Heart Regenerative Medicine Clinic at Cedars-Sinai offers consultative services for patients with heart and vascular disease who may qualify for investigative stem cell therapy. The goal is to devise a comprehensive treatment strategy for patients who remain symptomatic on their current management regimen, or for patients with stable heart disease who are concerned about disease progression. As part of the overall assessment, we evaluate candidacy of participation in clinical trials at Cedars-Sinai.
In addition to groundbreaking clinical trials performed at Cedars-Sinai, we are aware of other important stem cell trials being performed at institutions across the nation. During an evaluation, a patient may not meet criteria for participation in a Cedars-Sinai clinical trial; however, will be eligible for a clinical trial at another institution. If the patient is willing to travel there, our physicians will work closely with researchers at that location to expedite referrals and seamlessly transfer all relevant medical records.
While the Smidt Heart Institute Regenerative Medicine Clinic will accept inquiries directly from patients and their families, we prefer to work closely with referring physicians. Our team has found that physician collaboration allows for devising the best treatment and follow-up options individualized for each patient.
The services of the Regenerative Medicine Clinic cover a broad range of cardiovascular disorders including:
- Ischemic heart disease (angina, myocardial infarction, ischemic cardiomyopathy)
- Heart failure (ischemic cardiomyopathy, dilated cardiomyopathy, postpartum cardiomyopathy)
- Congenital heart disease (right ventricular failure, muscular dystrophy)
- Pulmonary arterial hypertension
- Peripheral arterial disease (intermittent claudication, critical limb ischemia)
Not everyone will be appropriate for evaluation by our clinic. We currently are not equipped to handle a number of disorders, and we must consider a number of factors (such as multisystem failure or concurrent malignancies) that may disqualify people from participation in relevant clinical trials. The first step is to contact us for a preliminary evaluation.
Pictured above are members of the Heart Institute Regenerative Medicine Clinic: from left, Timothy Henry, MD, Rachel Smith, PhD, Michelle Kittleson, MD, and Eduardo Marbán, MD, PhD.